Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Lung Cancer

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2013.07.007PMID 23948549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion

  2013cited by this paper
• Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

  2012cited by this paper
• First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

  2012cited by this paper
• Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis

  2011cited by this paper
• The use of the PleurX catheter in the management of non-malignant pleural effusions

  2011cited by this paper
• Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer

  2011cited by this paper
• A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder.

  2011cited by this paper
• Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

  2009cited by this paper
• Monoclonal anti‐vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion

  2009cited by this paper
• EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion.

  2009cited by this paper
• Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients

  2009cited by this paper
• Analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells of sentinel lymph nodes in breast cancer.

  2008cited by this paper
• Talc Pleurodesis for Malignant Effusions Is Preferred Over the PleurX Catheter (Pro Position)

  2007cited by this paper
• FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

  2007cited by this paper
• Angiogenic Factors and Angiogenesis Inhibitors in Exudative Pleural Effusions

  2005cited by this paper
• Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy1

  2004cited by this paper
• BTS guidelines for the management of malignant pleural effusions.

  2003cited by this paper
• Malignant pleural effusions.

  2002cited by this paper
• Vascular endothelial growth factor: the key mediator in pleural effusion formation

  2002cited by this paper
• High Level of Vascular Endothelial Growth Factor in Hemorrhagic Pleural Effusion of Cancer

  2002cited by this paper
• Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

  2001cited by this paper
• Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer

  1999cited by this paper
• Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions

  1999cited by this paper
• Implantable access system for prolonged intrapleural immunotherapy.

  1994cited by this paper
• Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production.

  1991cited by this paper
• Absence of Mesothelial Cells from Tuberculous Pleural Effusions

  1960cited by this paper

• Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion

  2025cites this paper
• Retrospective prognostic evaluation and single-cell transcriptomic analyses of non-small cell lung carcinoma with malignant pleural effusion

  2025cites this paper
• Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer

  2023cites this paper
• A meta-analysis of Th1 and Th2 cytokine profiles differentiating tuberculous from malignant pleural effusion

  2022cites this paper
• Monocytes subtypes from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy

  2022cites this paper
• The Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion

  2022cites this paper
• Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?

  2021cites this paper
• Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review).

  2021cites this paper
• Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis

  2021cites this paper
• Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone

  2020cites this paper
• Making cold malignant pleural effusions hot: driving novel immunotherapies

  2019cites this paper
• Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients

  2019cites this paper
• Systematic review and meta‐analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions

  2016influential citation
• Small cell lung cancer: Recruitment of macrophages by circulating tumor cells

  2016cites this paper
• Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases

  2016cites this paper
• Pleuranesteen VEGF-konsentraation korrelaatio kuolleisuuteen ja pleurafuusion onnistumiseen tunneloitavalla pleurakatetrilla (Pleur-X) malignia pleuranesteilyä sairastavilla potilailla

  2015cites this paper
• miR141–CXCL1–CXCR2 Signaling–Induced Treg Recruitment Regulates Metastases and Survival of Non–Small Cell Lung Cancer

  2014cites this paper
• miR-141-CXCL1-CXCR2 signaling-induced Treg cells recruitment regulates metastases and survival of non-small cell lung cancer

  2014cites this paper